Therapy News and Research

RSS

Enrollment begins in Boston Scientific's vagal nerve stimulation trial for heart failure

Boston Scientific Corporation has enrolled the first patients in its NECTAR-HF (NEural Cardiac TherApy foR Heart Failure) clinical trial. NECTAR-HF is a prospective, randomized, international clinical feasibility study designed to assess preliminary safety and efficacy of chronic vagal nerve stimulation in heart failure patients.

30 Sep 2011

Cardiac Dimensions' enhanced version of CARILLON system receives CE Mark approval

Cardiac Dimensions, Inc. today announced that it has received Conformite Europeenne (CE) Mark approval for a newly enhanced version of its CARILLON Mitral Contour System, a novel therapy for treating heart failure patients suffering from functional mitral regurgitation.

30 Sep 2011

Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors

Circadian Technologies Limited (ASX: CIR, OTCQX:CKDXY) is extremely proud to announce that its 100% owned subsidiary, Vegenics Pty Ltd, has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate clinical studies of VGX-100. The first trial (Phase I) will involve the treatment of a variety of different cancer types in patients with late stage cancer.

29 Sep 2011

Stroke risk increases with even small rises in blood pressure

Small rises of blood pressure may greatly increase a person's risk of stroke, according to new research. The study review, published in the journal Neurology, analyzed the results of 12 studies on blood pressure and stroke incidences among a total of 518,520 adults.

29 Sep 2011

CVS Caremark, Dovetail Health partner to prevent avoidable hospital readmissions

Industry research finds that one in five seniors are readmitted to the hospital within 30 days of discharge, representing a prevalent and costly issue for health plan sponsors. Moreover, it is estimated that nearly 70 percent of adverse health events that take place after hospital discharge are related to medication management issues.

29 Sep 2011

Almirall seeks European approval for linaclotide to treat irritable bowel syndrome with constipation

Almirall, S.A. announced today that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for linaclotide, an investigational guanylate cyclase-C (GC-C) receptor agonist for the treatment of irritable bowel syndrome with constipation (IBS-C). Once approved, linaclotide will be marketed in Europe under the trademark Constella®.

29 Sep 2011

IRIN examines rise in new leprosy cases in remote region of Madagascar

IRIN examines an increase in new leprosy cases in Antalaha, a once-prosperous vanilla-exporting town in a remote region of Madagascar, where a 2009 military-supported coup brought the suspension of some foreign aid and trade benefits.

29 Sep 2011

Intensive blood glucose control therapy provides no added benefit against cognitive decline in older diabetics

Intensive control of blood sugar levels beyond standard targets provides no additional protection against cognitive decline in older people with diabetes than standard treatment, according to a national study coordinated by researchers at Wake Forest Baptist Medical Center.

29 Sep 2011

Cubist plans to move CB-183,315 into Phase 3 trial for treatment of CDAD

Cubist Pharmaceuticals, Inc. today announced it plans to move CB-183,315, being studied for the treatment of a severe and sometimes life-threatening diarrhea caused by Clostridium difficile known as C. difficile-associated diarrhea, or CDAD, into late-stage trials.

29 Sep 2011

Researchers use patient's own stem cells to correct genetic alteration that causes SCD

Using a patient's own stem cells, researchers at Johns Hopkins have corrected the genetic alteration that causes sickle cell disease (SCD), a painful, disabling inherited blood disorder that affects mostly African-Americans. The corrected stem cells were coaxed into immature red blood cells in a test tube that then turned on a normal version of the gene.

29 Sep 2011

Cincinnati Children's to conduct first pediatric migraine medicine clinical trial

Cincinnati Children's Hospital Medical Center has received a $12 million grant from the National Institutes of Health to conduct the first clinical trial to determine the medication of choice for preventing migraines in children and teens.

29 Sep 2011

Prototype drug shows promise against chronic lymphocytic leukemia

Pre-clinical research has generated some very promising findings about a prototype drug for the treatment of chronic lymphocytic leukemia.

29 Sep 2011

Johns Hopkins researchers discover oxaliplatin-based nerve damage

Oxaliplatin, a platinum-based anticancer drug that's made enormous headway in recent years against colorectal cancer, appears to cause nerve damage that may be permanent and worsens even months after treatment ends.

29 Sep 2011

Intensive therapy at early ages improves social-communication skills in children with ASD

A primary characteristic of autism spectrum disorders (ASD) is impairments in social-communication skills. Children and adolescents with social-communication problems face difficulty understanding, interacting and relating with others. University of Missouri researchers found that children who receive more intensive therapy to combat these impairments, especially at early ages, achieve the best outcomes.

29 Sep 2011

SanBio initiates SB623 Phase 1/2a clinical trial in ischemic stroke

SanBio, Inc. has announced that a patient at Stanford University Medical Center has become the first to be treated with SB623, a novel cell therapy for patients with disability resulting from ischemic stroke.

29 Sep 2011

Dynatronics fourth quarter sales increase 3% to $8,190,382

Dynatronics Corporation today announced results for its fiscal fourth quarter and year ended June 30, 2011.

28 Sep 2011

Long-term morbidity and mortality of NAFLD patients with advanced fibrosis, cirrhosis

Patients with non-alcoholic fatty liver disease (NAFLD) with advanced fibrosis or cirrhosis have a lower incidence of liver-related complications and hepatocellular carcinoma (HCC) than patients infected with hepatitis C virus (HCV), according to the prospective study published in the October issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

28 Sep 2011

'Urgent action' needed to prevent resistance to antiretroviral therapy

"The clear pattern of increasing antiretroviral resistance in lower-income settings must be considered in the context of the worldwide HIV-control agenda," especially because "the increasing rates of antiretroviral resistance in low-income settings represent a potential threat to the emerging treatment-as-prevention strategy," Evan Wood and Julio Montaner of the BC Centre for Excellence in HIV/AIDS write in a Lancet Infectious Diseases opinion piece.

28 Sep 2011

Treatment of CMV infection can inhibit medullablastomas development

Researchers at Karolinska Institutet in Sweden have demonstrated for the first time that it is possible to inhibit the growth of brain tumours by treating the common Cytomegalovirus (CMV). The virus, which is found in a wide range of tumour types, offers a possible route towards controlling tumour growth and reducing the size of the tumour as a complement to conventional cytotoxin-based therapies.

28 Sep 2011

IUPUI develops mathematical model of brain's neural circuitry

Researchers from the School of Science at Indiana University-Purdue University Indianapolis have developed a mathematical model of the brain's neural circuitry that may provide a better understanding of how and why information is not transmitted correctly in the brains of Parkinson's disease patients. This knowledge may eventually help scientists and clinicians correct these misfires.

28 Sep 2011

Therapy News and Research

Enrollment begins in Boston Scientific's vagal nerve stimulation trial for heart failure

Cardiac Dimensions' enhanced version of CARILLON system receives CE Mark approval

Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors

Stroke risk increases with even small rises in blood pressure

CVS Caremark, Dovetail Health partner to prevent avoidable hospital readmissions

Almirall seeks European approval for linaclotide to treat irritable bowel syndrome with constipation

IRIN examines rise in new leprosy cases in remote region of Madagascar

Intensive blood glucose control therapy provides no added benefit against cognitive decline in older diabetics

Cubist plans to move CB-183,315 into Phase 3 trial for treatment of CDAD

Researchers use patient's own stem cells to correct genetic alteration that causes SCD

Cincinnati Children's to conduct first pediatric migraine medicine clinical trial

Prototype drug shows promise against chronic lymphocytic leukemia

Johns Hopkins researchers discover oxaliplatin-based nerve damage

Intensive therapy at early ages improves social-communication skills in children with ASD

SanBio initiates SB623 Phase 1/2a clinical trial in ischemic stroke

Dynatronics fourth quarter sales increase 3% to $8,190,382

Long-term morbidity and mortality of NAFLD patients with advanced fibrosis, cirrhosis

'Urgent action' needed to prevent resistance to antiretroviral therapy

Treatment of CMV infection can inhibit medullablastomas development

IUPUI develops mathematical model of brain's neural circuitry

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News